Adial Pharmaceuticals (ADIL) Return on Capital Employed (2022 - 2024)
Adial Pharmaceuticals' Return on Capital Employed history spans 3 years, with the latest figure at 1.05% for Q3 2024.
- For Q3 2024, Return on Capital Employed rose 201.0% year-over-year to 1.05%; the TTM value through Sep 2024 reached 1.05%, up 201.0%, while the annual FY2023 figure was 1.5%, N/A changed from the prior year.
- Return on Capital Employed for Q3 2024 was 1.05% at Adial Pharmaceuticals, down from 0.86% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 0.86% in Q2 2024 and bottomed at 3.74% in Q1 2023.
- The 3-year median for Return on Capital Employed is 2.17% (2023), against an average of 2.12%.
- The largest annual shift saw Return on Capital Employed skyrocketed 54bps in 2023 before it skyrocketed 265bps in 2024.
- A 3-year view of Return on Capital Employed shows it stood at 2.44% in 2022, then rose by 22bps to 1.91% in 2023, then soared by 45bps to 1.05% in 2024.
- Per Business Quant, the three most recent readings for ADIL's Return on Capital Employed are 1.05% (Q3 2024), 0.86% (Q2 2024), and 1.09% (Q1 2024).